ReHerbal

09/03/2026

Only few spaces left!

Find a full description at

https://share.google/keHWbanO8XYglXMBl

07/02/2026

Find a full description at

https://share.google/keHWbanO8XYglXMBl

04/02/2026

Please enjoy this podcast, recorded after the MediHerb Unplugged livestream. I revisit unanswered practitioner questions and explore them in greater depth.

The discussion spans berberine-containing herbs, St Mary’s Thistle and the gut, and evidence-based perspectives on Echinacea and Withania in autoimmunity and endometriosis.

I also examine time-restricted eating, metabolic and longevity pathways, plaque stabilisation, APOE4 and dementia risk, and herbal considerations in Parkinson’s disease.

If you’re navigating complex, chronic cases, this podcast offers practical frameworks grounded in both research and clinical experience.

The episode is available on the Integria Practitioner Education Centre as well as Spotify, Apple Podcasts and Podbean.

https://practitioner.integria.com/series-the-mediherb-podcast
https://open.spotify.com/episode/5intpO3WpvfHJM7a2z801w

22/01/2026

One last space available!
Each month we explore 7 different essential oils and how they can influence the way you feel emotionally & physically.
Join us if you enjoy learning through direct experience rather than theory.

03/01/2026

Social media has become our second life, for some, even the main one. With so much information, it's hard to tell who is authentic and who is not.
It feels like everyone is a master.
A weekend course, a certificate, a new title in the bio, and suddenly authority is assumed.
Confidence is not competence.
Wisdom usually sounds quieter than marketing.
Depth doesn't come from speed.
It comes from years of practice, mistakes, humility, and learning how little you actually know.
Some paths ask for time, patience and responsibility, especially when you're working with people.
Choose carefully who you follow.

05/12/2025

12/11/2025

Don't forget to book in, limited spaces only!
Last Aromatherapy workshop in in 2025, the new series will start in January 2026!

09/10/2025

Given new clinical research suggesting calming and sleep-promoting effects for Aloysia citriodora (lemon verbena), a new study aimed to assess its behavioural, cognitive, psychological and physiological effects in children exhibiting symptoms of attention deficit hyperactivity disorder (ADHD) at the sub-clinical level.

This exploratory study followed a randomised, double blind, parallel group design, wherein 120 healthy participants aged 8 to 17 years received either 15 mg/kg of lemon verbena extract (LVE) or a matched placebo for 56 days.

Participants who received LVE reported greater subjective fatigue, defined as reduced energy levels according to the Profile of Mood States subscale, without impairment in cognitive performance (p=0.001), compared to placebo. The authors interpreted this as a “calming/de-energising” effect.

Parent-rated Conners-3 H/I (hyperactivity/impulsivity) showed a near-significant advantage for LVE (p=0.052). At Day 56 (exploratory pairwise), parent assessed H/I was significantly lower for LVE (p=0.045); child self-reports showed a similar trend (p=0.080).

Main limitations of the trial were that it was underpowered (not enough participants) and had a baseline imbalance: the LVE group had worse mood/behaviour at baseline. Also, the chosen population only exhibited sub-clinical symptoms (not diagnosed ADHD).

No details were provided as to how the lemon verbena dry extract correlated to original starting herb, but it was probably around a 5:1 concentrate. So, the dose for a 30 Kg child would be equivalent to around 2.5 g of leaf.

For more information see: https://pubmed.ncbi.nlm.nih.gov/40251851/

09/10/2025

A recent study aimed at investigating the effects of pomegranate juice (POMJ) consumption on inflammatory biomarkers and gene expression in patients with IBD in clinical remission, but at high risk for relapse (baseline faecal calprotectin ≥100 µg/g). In this randomised, placebo-controlled, parallel trial, 16 people with IBD (CD 6 (38%) UC 10 (62%)) consumed POMJ or placebo for 12 weeks. The active to placebo allocation was 2:1, given the low number of participants.

POMJ consumption significantly reduced faecal calprotectin (by around 2.4 times) and plasma endotoxin levels. Transcriptomic analysis of peripheral blood mononuclear cells revealed upregulation of genes involved in mucosal immunity, including the aryl hydrocarbon receptor (AHR), neutrophil cytosolic factor 4 (NCF4) and nuclear factor, interleukin 3 regulated (NFIL3).

Urolithin metabotypes are classifications of individuals based on their gut microbiota’s ability to metabolise the phytochemicals ellagitannins and ellagic acid (found in pomegranate, berries and walnuts) into urolithins, bioactive metabolites with anti-inflammatory and mitochondrial benefits. Urolithin metabotypes in the trial participants were predominantly of the B type, associated with intestinal dysbiosis.

The dose of the 100% pomegranate juice was 125 mL twice daily (~>700 mg/day ellagitannins). This is a therapeutically significant amount of actives that can be readily replicated by using an extract of pericarp in tablet or liquid form.
The significance of the finding is limited by the very small sample (n = 16) and the 2:1 randomisation, conferring limited power, especially for between-group comparisons and subgroup (UC vs CD) inferences. Also, it was a short trial (12 weeks) with no assessment of clinical endpoints or histological healing; endoscopic and mucosal cytokine panels did not change. But there is mechanistic plausibility: the upregulation of AHR/NCF4/NFIL3 and pathway modelling align with improved barrier/immune homeostasis, and are biologically consistent with the faecal calprotectin/endotoxin findings. It is, as the authors noted, a proof-of-principle study, with the observed benefits likely due to a modulation of the gut microbiome.

For more information see: https://pubmed.ncbi.nlm.nih.gov/40255128/